Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. (Q38679359)
Jump to navigation
Jump to search
scientific article published on 15 December 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. |
scientific article published on 15 December 2015 |
Statements
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study (English)
James C Yao
Simron Singh
Roberto Buzzoni
Carlo Carnaghi
Edward Wolin
Jiri Tomasek
Markus Raderer
Harald Lahner
Maurizio Voi
Lida Bubuteishvili Pacaud
Nicolas Rouyrre
Carolin Sachs
Juan W Valle
Gianfranco Delle Fave
Eric Van Cutsem
Margot Tesselaar
Yasuhiro Shimada
Do-Youn Oh
Jonathan Strosberg
Matthew H Kulke
Marianne E Pavel
RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group
17 December 2015